Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.

Trial Profile

Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Feb 2010 Primary endpoint results published in the Journal of Hepatology : 4 Feb 2010
    • 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.(NCT00104052).
    • 20 Oct 2009 Actual initiation date changed from Jul 2007 to Feb 2005 as reported by ClinicalTrials.gov record (NCT00104052).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top